Moderna and BARDA Sign COVID-19 Vaccine Development Contract
Moderna is deploying its mRNA expertise to immunization development
Washington has signed on another biotech firm to help find a vaccine solution to COVID-19. Moderna and the Biomedical Advanced Research and Development Authority (BARDA) have entered into an agreement to accelerate the development of an immunization for COVID-19. BARDA is a unit of the Health and Human Services Office of the Assistant Secretary for Preparedness and Response.
As a biopharmaceutical innovator Moderna has a COVID-19 vaccine candidate in a clinical trial for evaluation
Moderna launched a clinical trial in March 2020 to evaluate its COVID-19 vaccine. Patients administered the vaccine candidate are rigorously monitored. If the outcomes of the clinical trial are satisfactory, Moderna will submit its data and results to the FDA for review and potential approval.
Moderna has a unique approach to research & development
Founded in 2010 and headquartered in Cambridge, Massachusetts Moderna has established a highly specialized niche for itself in the biotech community. Their research and product commercialization focus is centered on messenger ribonucleic acid (mRNA) sciences and solutions. Human cells use mRNA to direct the creation of proteins necessary to sustain biological functions within people including those actions that thwart disease.
What is mRNA?
Messenger RNA (mRNA) is a single-stranded RNA molecule that is complementary to a single DNA strand in a gene. An mRNA is an RNA form of the gene that exits the cell nucleus and travels to the cytoplasm where proteins are produced. Throughout protein synthesis, an organelle defined as a ribosome travels along the mRNA, scans its base sequence then uses the genetic code to decipher each three-base triplet (“codon”) into its matching amino acid.
Moderna’s product pipeline is impressive
As a company with approximately 700 associates (and growing), Moderna has an exciting variety of products in development. The therapeutic categories it is investigating include cardiology, immune disorders and oncology. These are some of the immunization products in Moderna’s pipeline:
- Cytomegalovirus (CMV)
- Epstein-Barr virus (EBV)
- hMPV/PIV3
- KRAS (pancreatic cancer immunization)
- Influenza H7N9
- PCV (personalized cancer vaccine)
- Respiratory syncytial virus (RSV)
- SARS-CoV-2 (COVID-19)
- Zika vaccine
Moderna and other vaccine companies are taking center stage
The COVID-19 pandemic has catapulted the importance of preventative healthcare and vaccine research into global prominence. It is clinically important to have multiple vaccine producers to be assured product is widely available and shortages are avoided if a vaccine manufacturer has production problems. The clinical trial results of Moderna’s COVID-19 candidate are highly anticipated. If results are good and the FDA approves their vaccine, Moderna’s clinical and commercial future will be extraordinarily rewarding for them plus patients and clinicians.
Thank you for reading this story
Read my other articles about medical and healthcare business trends, content marketing and digital strategy, brand and product management, consumer wellness, managed care and market access strategy. Contact me today for your healthcare content writing and content strategy needs.
I have over 20 years of experience in the healthcare industry producing valuable healthcare content for audiences and customers spanning physicians, nurses, pharmacists plus pharmaceutical companies, medical technology manufacturers, healthcare provider organizations, managed care, investors, consumers and other stakeholders.
Visit and connect…
As a healthcare content writer, my work aligns with an organization’s voice, brand, SEO elements, marketplace and objectives. It establishes trust in their company and recognized value in its products and services that generates revenue.
This experience was earned through working at Walgreens, Pfizer, AbelsonTaylor, TAP (Takeda Abbott Partnership), Hospira Worldwide and Boston Software Systems.
To a large degree, my professional interests emulate my family which includes doctors, nurses, physician assistants and other clinicians plus those that are working in healthcare administration and commercial enterprises.
